2009
DOI: 10.1517/17460440903490395
|View full text |Cite
|
Sign up to set email alerts
|

Discovery of estrogen receptor modulators: a review of virtual screening and SAR efforts

Abstract: With the goal of reducing toxicity and/or improving efficacy, challenges to the successful modeling of endocrine agents are proposed, providing new paradigms for the design of ER inhibitors.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
9
0

Year Published

2010
2010
2021
2021

Publication Types

Select...
7
1

Relationship

3
5

Authors

Journals

citations
Cited by 16 publications
(9 citation statements)
references
References 55 publications
0
9
0
Order By: Relevance
“…For example, ERα is more prevalent in the gonads, mammary glands, kidneys and bronchi, and it stimulates proliferative processes in cells. In turn, ERβ is predominant in bones and pulmonary alveoli, and it delivers antiproliferative effects ( 12 , 13 ). Unlike other steroid receptors, ERs bind to a wide range of exogeneous compounds, and are they are increasingly often classified as promiscuous receptors ( 14 ).…”
Section: Introductionmentioning
confidence: 99%
“…For example, ERα is more prevalent in the gonads, mammary glands, kidneys and bronchi, and it stimulates proliferative processes in cells. In turn, ERβ is predominant in bones and pulmonary alveoli, and it delivers antiproliferative effects ( 12 , 13 ). Unlike other steroid receptors, ERs bind to a wide range of exogeneous compounds, and are they are increasingly often classified as promiscuous receptors ( 14 ).…”
Section: Introductionmentioning
confidence: 99%
“…Since compounds already confirmed by experimental assays provide an opportunity to understand the basis of subtype selectivity, the development of models for predicting the subtype selectivity would allow for the development of more potent and selective compounds for these important pharmaceutical targets. In this context, QSARs can be of valuable assistance in predicting the estrogenic activity of certain molecules [ 12 ].…”
Section: Introductionmentioning
confidence: 99%
“…The ERα and ERβ subtypes are coded by different genes, ESR1 and ESR2 respectively, and are distributed and play multiple roles in a tissue-dependent manner. For example, the ERα is more prevalent in the gonads, mammary glands, kidney and lung bronchi, while ERβ predominates in bone, lung alveoli and prostate tissues [ 5 , 13 , 14 ]; furthermore, ERα has been found to promote cell proliferation while ERβ possesses an anti-proliferative effect in the mammary tissues [ 15 , 16 , 17 ]. The ERα and ERβ appear to share a modest 47% [ 10 , 18 ] and 56% [ 5 ], respectively, overall and ligand binding domain (LBD) sequence identity; yet, only two residues among those that line the binding pocket are found to be different: Leu384 (ERα) vs. Met336 (ERβ) and Met421(ERα) vs. Ile373 (ERβ) [ 5 ] ( Figure 2 ).…”
Section: The Estrogen Receptorsmentioning
confidence: 99%